FRAZER, Pennsylvania—The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in…
PINE BROOK, New Jersey—Elusys Therapeutics Inc.’s injectable anthrax antitoxin, branded Anthim (obiltoxaximab), became the newest member of the elite club of drugs to gain FDA…
Zurich-Schlieren, SWITZERLAND— Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company that is developing a powerful new class of therapies known as DARPins, today announced…
BANNOCKBURN, Ill. and COPENHAGEN, Denmark – Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and…
SAN DIEGO & PALO ALTO, California—Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and OMT, Inc. (Open Monoclonal Technology) announce the signing of agreements for Ligand to acquire…
ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (MOLN) announced today that the company has achieved a top 3 ranking in the category “Most Innovative Newcomer” at the Euro-pean…
PINE BROOK, New Jersey – Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded its first delivery order under a procurement contract for Anthim…
ZURICH, Switzerland—Molecular Partners AG (MOLN) announced today that it has been honored with the EUROPEAN BIOTECHNICA AWARD 2015. The award honors one company that has…